Gilead Sciences has made lenacapavir, an effective HIV prevention drug, cheaper in 120 low- and middle-income countries, yet many high-burden nations remain excluded.
Although lenacapavir has demonstrated significant effectiveness, particularly among women and men in various trials, affordability remains critical for wider access to HIV prevention.
Critics argue that Gilead's direct agreements for lenacapavir will limit access in excluded upper middle-income countries, particularly in Latin America, where HIV is on the rise.
The price disparity for lenacapavir, sold at $42,250 in the US versus a potential production cost of $40, highlights the urgency for equitable global distribution.
Collection
[
|
...
]